Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a smartphone replace clinic visits for rare tumor survivors?

NCT ID NCT04573816

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests whether a remote monitoring program can reliably track the health of people who have had surgery for pheochromocytoma or paraganglioma (PPGL), rare adrenal tumors. Participants use an internet platform to report their data, which is compared to information collected during in-person clinic visits. The goal is to see if remote monitoring can be as reliable as standard follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If reliable, this remote monitoring program could reduce the need for frequent in-person clinic visits for patients with these rare tumors.
What could go wrong
The study is small and single-center, so results may not apply broadly. It only measures reliability of data collection, not long-term health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

132 people

The number who actually took part.

Started

Oct 2020

Finished

Oct 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with pheochromocytoma or paraganglioma surgery

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient at least 18 years old * Follow-up after surgery of a pheochromocytoma or a paraganglioma at the European Hospital Georges Pompidou (Paris, France) * Free from recurrences and / or metastases at inclusion * Non-opposition of participation in research Exclusion Criteria: * Lack of internet access * Patient not understanding French * Patient living abroad, unable to come for consultation * Patient with co-morbidity involving life threatening within one year of inclusion * Pregnant or breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Paraganglioma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

paraganglioma pheochromocytoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Paraganglioma Pheochromocytoma

Contacts and locations

Locations

  • Hopital européen Georges Pompidou

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.